Prostate Metabolism, Cancer Risk and Gut Microbiota
Launched by TURKU UNIVERSITY HOSPITAL · Oct 30, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Prostate Metabolism, Cancer Risk and Gut Microbiota," is looking into how the bacteria in our gut might be linked to prostate cancer and prostate hyperplasia (a condition where the prostate gland enlarges). Researchers want to understand if there is a connection between these gut bacteria and the risk of developing prostate cancer. The study is currently recruiting male participants aged 65 to 74 who are willing to sign an informed consent form and follow the study procedures.
If you choose to participate, you’ll be involved in a study that aims to uncover important information about prostate health. It’s essential that you feel comfortable with all the steps of the study, as compliance is key for accurate results. If you have any concerns about your ability to participate, it’s best to discuss them before enrolling. Overall, this study could provide valuable insights that may help improve our understanding of prostate cancer risk in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Provision of signed and dated informed consent form.
- • Ability and stated willingness to comply with all study procedures and availability for the duration of the study.
- Exclusion Criteria:
- • inability to comply with study procedures or unwillingness to participate in the study.
About Turku University Hospital
Turku University Hospital (TYKS) is a leading academic medical center located in Turku, Finland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key institution within the University of Turku, TYKS integrates cutting-edge medical education with state-of-the-art clinical services, offering a broad spectrum of specialized care. The hospital actively participates in clinical trials, facilitating the translation of scientific discoveries into practical treatments, and enhancing patient outcomes. With a multidisciplinary approach and a focus on collaboration, TYKS aims to contribute significantly to the global medical community through its rigorous research initiatives and commitment to patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Turku, , Finland
Patients applied
Trial Officials
Peter J. Bostrom, MD, PhD
Principal Investigator
Turku University Hospital and University of Turku
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported